Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
Treating Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications with Savolitinib
Gastric Cancer|Esophagogastric Junction Disorder
DRUG: Savolitinib
Objective response rate (ORR) evaluated by the Independent Review Committee (IRC) (RECIST 1.1 criteria), To evaluate the efficacy of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months
Progression-free survival (PFS) (RECIST 1.1 criteria), Efficacy of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications, From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months|incidence of various adverse events (AE), To evaluate the safety and tolerability of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications, through study completion, an average of 3.5 year
This is a single-arm, multi-cohort, multi-center, open-label, phase II clinical study. The objective is to evaluate the efficacy and safety of Savolitinib in the treatment of locally advanced or metastatic Gastric Cancer and Esophagogastric junction adenocarcinoma Patients with MET gene amplifications. The study involves a Screening Period, a Treatment Period and a Follow-up Period. It is planned that about 30 study sites will enroll 75 patients